VRX up +0.87% percent Today $VRX High is at 133.21 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 11:47 AM

VRX up +0.87% percent Today $VRX High is at 133.21 and the Low 131.34 with current volume of 539,926.

Recent News posted below.

Valeant Pharmaceuticals International VRX other info.
http://investorshangout.com/Valeant-Pharmaceu...VRX-53038/

VRX Valeant Pharmaceuticals International Recent Headline News

Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST

ZTS: 43.07 (-0.17), AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), ACT: 243.26 (+1.63)

Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.07 (-0.17), AGN: 197.17 (+0.96), ACT: 243.26 (+1.63), VRX: 133.21 (+1.31)

Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey
CNW Group - Thu Nov 13, 4:00PM CST
Expansion of its U.S. headquarters solidifies commitment to grow jobs and support the local economy
VRX: 133.21 (+1.31), VRX.TO: 150.54 (+0.39)

Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), ACT: 243.26 (+1.63)

Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.07 (-0.17), AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), ACT: 243.26 (+1.63)

Cramer Says Zoetis Could Be Next M&A Target for Ackman, Valeant
at The Street - Wed Nov 12, 10:37AM CST
Bill Ackman has a stake in Valeant Pharmaceuticals, as well as Zoetis, the latter of which may become a takeover target by the former, Jim Cramer says.
ZTS: 43.07 (-0.17), VRX: 133.21 (+1.31)

Today's Market: Mergers, Rumors And Earnings Moving These Stocks
Matthew Smith - at Seeking Alpha - Wed Nov 12, 10:04AM CST

ZTS: 43.08 (-0.16), T: 35.81 (+0.20), VRX: 133.21 (+1.31), FOSL: 106.87 (-2.94), BBT: 37.67 (+0.09), PFE: 30.30 (-0.12), KORS: 71.57 (+0.83), SUSQ: 13.14 (+0.08)

Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.08 (-0.16), AGN: 197.17 (+0.96), HLF: 37.53 (-0.32), VRX: 133.21 (+1.31), PFE: 30.30 (-0.12), MRK: 58.96 (-0.58), LLY: 67.48 (-0.20)

Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST

AGN: 197.17 (+0.96), VRX: 133.21 (+1.31)

Wall Street Breakfast: Global Banks Fined $3.4B In Forex Probe
Wall Street Breakfast - Seeking Alpha - Wed Nov 12, 5:30AM CST
Economy Japanese stocks scaled seven-year highs this morning on further speculation that Prime Minister Shinzo Abe will postpone a planned sales tax hike and call a general election for December. The Sankei newspaper reported that Abe would...
VRX: 133.21 (+1.31), MDT: 69.07 (-0.31), C: 53.40 (-0.04), WMT: 82.43 (-0.51), RBS: 11.78 (+0.03), UBS: 17.52 (-0.02), NOK: 7.82 (-0.44), YHOO: 51.06 (+0.56), PBR: 9.64 (-0.56), SPY: 204.20 (+0.01), SAP: 66.52 (-0.11), EBAY: 54.38 (+0.01), JPM: 60.50 (+0.27), BHP: 57.78 (+0.15), AAPL: 113.95 (+1.13), BCS: 14.55 (+0.12), FRM: 6.23 (-0.03), COV: 93.85 (+0.18), HSBC: 50.21 (+0.06), FRGI: 56.74 (+0.31), ZTS: 43.08 (-0.16), DLA: 10.45 (-0.10), QQQ: 103.09 (+0.19), AOL: 46.53 (+0.16), BABA: 114.78 (-0.06)

Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), ACT: 243.26 (+1.63)

Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST

AGN: 197.17 (+0.96), ZTS: 43.08 (-0.16), ACT: 243.26 (+1.63), VRX: 133.21 (+1.31)

Zoetis jumps 6% on report of Ackman stake
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 2:48PM CST

ZTS: 43.08 (-0.16), VRX: 133.21 (+1.31)

Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.76 (+0.01), AGN: 197.17 (+0.96), ACT: 243.26 (+1.63), VRX: 133.21 (+1.31), MDT: 69.07 (-0.31), SLXP: 99.53 (+2.54), SNY: 46.42 (-0.11)

Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 89.18 (+0.10), VRX: 133.21 (+1.31), ALXN: 189.17 (-4.42), AMGN: 158.43 (-2.42), MYL: 53.86 (-0.87), ILMN: 180.14 (-4.86), CELG: 103.74 (-3.69)

Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), AUXL: 32.25 (-0.10), SLXP: 99.53 (+2.54)

Valeant Pharmaceuticals Sends Letter To Physician Customers
CNW Group - Fri Nov 07, 4:00PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today sent a letter to physician customers in order to address misconceptions and clarify how Valeant operates its business.
VRX: 133.21 (+1.31), VRX.TO: 150.54 (+0.39)

Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 197.17 (+0.96), VRX: 133.21 (+1.31), DVA: 77.34 (+0.30), GILD: 102.26 (-1.94), SLXP: 99.53 (+2.54), ICPT: 159.07 (+0.21), HUM: 137.35 (-1.06)

Bausch Health Companies Inc. (BHC) Stock Research Links

BHC Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hansa's Idefirix Shows Promise for Kidney Transplants

Compelling Progress from Hansa Biopharma Y'know, navigating through the biotech jungle isn't for the faint-hearted. Hansa Biopharma's recent results with Idefirix could just be the beacon of hope for patients struggling on transplant lists. Announced at the ASN Kidney Week—a name that's got weight, by the way—these findings aren't just filling space. They're promising...

Concierge Hybrid Choice™: Transforming Patient Care

A New Way to Nurture Patient Relationships This isn't just another cookie-cutter patient care program rolling out—it’s a genuine shake-up in the way doctors connect with their patients. Rishika Kaundal, MD, a dedicated family medicine physician, is pioneering change in Midlothian, Virginia with her Hybrid Choice™ concierge program. This isn't a fluff piece; it's a...

Dimethylaminopropylamine Market Eyes $732M by 2035

Surfactants and Epoxy Fuel Dimethylaminopropylamine Demand Hot off the presses, folks! Dimethylaminopropylamine, or DMAPA if you're into acronyms, is gearing up for a steady climb to a $731.9 million market value by the year 2035. That's quite the leap from the $452.6 million we saw back in 2025. According to Credence Research's latest estimates, this amine is hitching...

BOB Raises $5.5M for AI Banking Platform Revolution

Cracking the Code of Small Business Finance BOB, a Miami hotshot aiming to be more than just another fintech flash in the pan, has wrangled a sweet $5.5 million in seed capital. They're shaking hands with big names like Peter Thiel and the mastermind behind Plaid, Zak Perret, through Mischief Ventures. The plan? To build an AI-powered finance savior for small businesses...

First Citizens Surprises with Q3 Gains and Buyback Plan

Unexpected Third Quarter Tailwinds for First Citizens There are days in this trading gig when a bank I'll barely sneeze at hits out of the park. First Citizens BancShares (NASDAQ:FCNCA) pulled off such a feat, wringing out a third-quarter 2026 performance that beat their own benchmarks. They threw $600 million back to shareholders in repurchased stocks while repaying an...

Blockchain Boom: Media Market to Hit $3.33B by 2035

Blockchain is Not Just for Bitcoin Anymore Who would've thought, right? Blockchain's no longer just the playground for cryptocurrency enthusiasts. Today, it's making waves in the media and entertainment sector. Latest numbers from Credence Research have this market set to explode from $748 million in 2025 to a jaw-dropping $3.33 billion by 2035. Yeah, folks, that's a...

Concrete Admixtures Market: A Billion-Dollar Boom

A Look Under the Hood of Concrete Admixtures It's a concrete jungle out there, folks—literally. The once overlooked market of concrete admixtures is gearing up for quite the makeover, projected to hit USD 35.87 billion by 2035. For those of you tuning in, we're talking about chemicals that mix into your average concrete to change its properties. And, believe it or not,...

Estrogen Patch Struggles: Menopause Care Needs a Boost

Troublesome Estrogen Patch Shortages Hit Hard You'd think getting a prescription filled would be a simple task, right? Well, think again. Midi Health shines a glaring light on how the supposed ease of getting hormone therapy is anything but for many women in 2026. Out of those scrambling for estradiol patches, 44% hit roadblocks in pharmacies, and a third hit an all-out...

CardVault by Tom Brady Expands to Pittsburgh

Tom Brady’s CardVault Hits Pittsburgh’s Historic Strip District Pittsburgh just got another feather in its cap with CardVault by Tom Brady marking its 20th store at The Terminal. As if this city needed more sports excitement! Pittsburgh, with its die-hard Steelers, Penguins, and Pirates fans, snags a premium spot for sports collectibles. A Prime Spot for Serious...

Stephen A. Smith Calls for Corporate Support of HBCUs

A Stand for Education at the White House Stephen A. Smith stirred the pot with his decision to attend a White House dinner, a move that had tongues wagging across the media landscape. But this time, it wasn't about the usual hustle and bustle of the sports world. Smith had his sights set on the big picture, specifically, the long-term financial stability of Historically...